Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Common Equity (2017 - 2025)

Catheter Precision (VTAK) has disclosed Common Equity for 9 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 43.43% to $6.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Dec 2025, down 43.43% year-over-year, with the annual reading at $6.7 million for FY2025, 43.43% down from the prior year.
  • Common Equity for Q4 2025 was $6.7 million at Catheter Precision, down from $6.8 million in the prior quarter.
  • The five-year high for Common Equity was $35.9 million in Q1 2023, with the low at $5398.0 in Q3 2023.
  • Average Common Equity over 5 years is $14.4 million, with a median of $13.2 million recorded in 2021.
  • The sharpest move saw Common Equity tumbled 99.96% in 2023, then soared 237506.52% in 2024.
  • Over 5 years, Common Equity stood at $13.7 million in 2021, then crashed by 32.28% to $9.3 million in 2022, then skyrocketed by 128.87% to $21.2 million in 2023, then plummeted by 44.52% to $11.8 million in 2024, then tumbled by 43.43% to $6.7 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $6.7 million, $6.8 million, and $6.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.